TY  - JOUR 
AU  - Coto-Segura, P.
AU  - Segú-Vergés, C.
AU  - Martorell, A.
AU  - Moreno-Ramírez, D.
AU  - Jorba, G.
AU  - Junet, V.
AU  - Guerri, F.
AU  - Daura, X.
AU  - Oliva, B.
AU  - Cara, C.
AU  - Suárez Magdalena, Olaya
AU  - Abraham, S.
AU  - Mas, J.M.
PY  - 2023
SN  - 1664-3224
UR  - http://hdl.handle.net/20.500.11940/21000
AB  - Background: Psoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes. Certolizumab pegol [CZP],...
LA  - eng
KW  - Humans
KW  - Certolizumab Pegol
KW  - Network Pharmacology
KW  - Psoriasis
KW  - Antibodies, Monoclonal, Humanized
KW  - Immunoglobulin Fab Fragments
KW  - Chronic Disease
TI  - A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis
DO  - 10.3389/fimmu.2023.1212981
T2  - Frontiers in Immunology
KW  - AS Ferrol
KW  - CHUF
VL  - 14
ER  -